{
    "root": "31682960-5372-00cf-e063-6294a90ab671",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Losartan Potassium",
    "value": "20250328",
    "ingredients": [
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "LOSARTAN POTASSIUM",
            "code": "3ST302B24A"
        }
    ],
    "indications": "losartan potassium tablets angiotensin ii receptor blocker ( arb ) indicated : \u2022 treatment hypertension , lower blood pressure adults children greater 6 years old . lowering blood pressure reduces risk fatal nonfatal cardiovascular events , primarily strokes myocardial infarctions . ( 1.1 ) \u2022 reduction risk stroke patients hypertension left ventricular hypertrophy . evidence benefit apply black patients . ( 1.2 ) \u2022 treatment diabetic nephropathy elevated serum creatinine proteinuria patients type 2 diabetes history hypertension . ( 1.3 )",
    "contraindications": "hypertension \u2022 usual adult dose : 50 mg daily . ( 2.1 ) \u2022 usual pediatric starting dose : 0.7 mg per kg daily ( 50 mg ) . ( 2.1 ) hypertensive patients left ventricular hypertrophy \u2022 usual starting dose : 50 mg daily . ( 2.2 ) \u2022 add hydrochlorothiazide 12.5 mg and/or increase losartan potassium tablets 100 mg followed increase hydrochlorothiazide 25 mg blood pressure response needed . ( 2.2 , 14.2 ) nephropathy type 2 diabetic patients \u2022 usual dose : 50 mg daily . ( 2.3 ) \u2022 increase dose 100 mg daily blood pressure response needed . ( 2.3 )",
    "warningsAndPrecautions": "losartan potassium tablets usp , 25 mg white off-white , film coated , oval shaped tablets debossed ' ' one side ' 5 ' side . ndc : 70518-3894-00 ndc : 70518-3894-01 ndc : 70518-3894-02 ndc : 70518-3894-03 packaging : 90 1 bottle plastic packaging : 90 1 bottle plastic packaging : 30 1 blister pack packaging : 100 1 bottle plastic store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0 f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0 f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "losartan potassium tablets contraindicated : \u2022 patients hypersensitive component product . \u2022 coadministration aliskiren patients diabetes .",
    "indications_original": "Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: \u2022\u00a0Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) \u2022\u00a0Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) \u2022\u00a0Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 )",
    "contraindications_original": "Hypertension \u2022\u00a0Usual adult dose: 50 mg once daily. ( 2.1 ) \u2022\u00a0Usual pediatric starting dose:\u00a0 0.7 mg per kg once daily (up to 50 mg). ( 2.1 ) Hypertensive Patients with Left Ventricular Hypertrophy \u2022\u00a0Usual starting dose: 50 mg once daily. ( 2.2 ) \u2022\u00a0Add hydrochlorothiazide 12.5 mg and/or increase losartan potassium tablets to 100 mg followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. ( 2.2 , 14.2 ) Nephropathy in Type 2 Diabetic Patients \u2022\u00a0Usual dose: 50 mg once daily. ( 2.3 ) \u2022\u00a0Increase dose to 100 mg once daily if further blood pressure response is needed. ( 2.3 )",
    "warningsAndPrecautions_original": "Losartan potassium tablets USP, 25 mg are white to off-white, film coated, oval shaped tablets debossed with 'I' on one side and '5' on the other side.\n                  \n                  \n                  NDC: 70518-3894-00\n                  NDC: 70518-3894-01\n                  NDC: 70518-3894-02\n                  NDC: 70518-3894-03\n                  \n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOTTLE PLASTIC \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0 F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0 F) [see USP Controlled Room Temperature].\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Losartan potassium tablets are contraindicated: \n    \u2022\u00a0In patients who are hypersensitive to any component of this product. \n    \u2022\u00a0For coadministration with aliskiren in patients with diabetes."
}